168 related articles for article (PubMed ID: 28397723)
1. Short-term Preoperative Octreotide for Thyrotropin-secreting Pituitary Adenoma.
Fang HJ; Fu Y; Wu HW; Sun YL; Li YF; Zhang YZ; Zhong LY
Chin Med J (Engl); 2017 Apr; 130(8):936-942. PubMed ID: 28397723
[TBL] [Abstract][Full Text] [Related]
2. Clinical Importance of Somatostatin Receptor 2 (SSTR2) and Somatostatin Receptor 5 (SSTR5) Expression in Thyrotropin-Producing Pituitary Adenoma (TSHoma).
Yu B; Zhang Z; Song H; Chi Y; Shi C; Xu M
Med Sci Monit; 2017 Apr; 23():1947-1955. PubMed ID: 28434012
[TBL] [Abstract][Full Text] [Related]
3. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long-term response to octreotide therapy.
Yoshihara A; Isozaki O; Hizuka N; Nozoe Y; Harada C; Ono M; Kawamata T; Kubo O; Hori T; Takano K
Endocr J; 2007 Feb; 54(1):133-8. PubMed ID: 17159301
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro response to octreotide LAR in a TSH-secreting adenoma: characterization of somatostatin receptor expression and role of subtype 5.
Gatto F; Barbieri F; Castelletti L; Arvigo M; Pattarozzi A; Annunziata F; Saveanu A; Minuto F; Castellan L; Zona G; Florio T; Ferone D
Pituitary; 2011 Jun; 14(2):141-7. PubMed ID: 21086053
[TBL] [Abstract][Full Text] [Related]
5. Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.
Gatto F; Barbieri F; Gatti M; Wurth R; Schulz S; Ravetti JL; Zona G; Culler MD; Saveanu A; Giusti M; Minuto F; Hofland LJ; Ferone D; Florio T
Clin Endocrinol (Oxf); 2012 Mar; 76(3):407-14. PubMed ID: 21848909
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
7. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
[TBL] [Abstract][Full Text] [Related]
8. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
9. Short-term preoperative octreotide treatment for TSH-secreting pituitary adenoma.
Fukuhara N; Horiguchi K; Nishioka H; Suzuki H; Takeshita A; Takeuchi Y; Inoshita N; Yamada S
Endocr J; 2015; 62(1):21-7. PubMed ID: 25273395
[TBL] [Abstract][Full Text] [Related]
10. The effect of preoperative short-term octreotide treatment to surgery in thyrotropin-secreting pituitary adenomas: a retrospective cohort study.
Zhao R; Fan K; Wan W
BMC Endocr Disord; 2023 Aug; 23(1):176. PubMed ID: 37587420
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and response cutoff of octreotide suppression test in thyrotrophin (TSH)-secreting pituitary adenomas.
Liu J; Yang Y; Duan L; Chai X; Zhu H; Deng K; Lian X; Yao Y
Clin Endocrinol (Oxf); 2023 Sep; 99(3):306-314. PubMed ID: 37144621
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure.
Zhang CF; Liang D; Zhong LY
Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988
[TBL] [Abstract][Full Text] [Related]
14. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
[TBL] [Abstract][Full Text] [Related]
15. Thyrotropin-producing pituitary adenoma associated with Graves' disease.
Koriyama N; Nakazaki M; Hashiguchi H; Aso K; Ikeda Y; Kimura T; Eto H; Hirano H; Nakano S; Tei C
Eur J Endocrinol; 2004 Nov; 151(5):587-94. PubMed ID: 15538937
[TBL] [Abstract][Full Text] [Related]
16. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs.
Rabbiosi S; Peroni E; Tronconi GM; Chiumello G; Losa M; Weber G
Thyroid; 2012 Oct; 22(10):1076-9. PubMed ID: 22947349
[TBL] [Abstract][Full Text] [Related]
17. Diagnosing Thyrotropin-Secreting Pituitary Adenomas by Short-Term Somatostatin Analogue Test.
Han R; Shen L; Zhang J; Xie J; Fang W; Sun Q; Bian L; Zhou Y; Wang S; Ning G; Wang W; Ye L
Thyroid; 2020 Sep; 30(9):1236-1244. PubMed ID: 32212919
[No Abstract] [Full Text] [Related]
18. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
[TBL] [Abstract][Full Text] [Related]
19. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
20. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
